Literature DB >> 6958210

Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.

A Chalmers, D Thompson, H E Stein, G Reid, A C Patterson.   

Abstract

Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with penicillamine. All patients had previous mucocutaneous reactions to chrysotherapy. Manifestations included pleurisy in five of six patients, rashes in three, nephritis in two, and neurologic disturbances in two; lupus erythematosus cells were found in five patients, antinuclear antibodies in all six, antideoxyribonucleic acid in three, positive Coombs' test results for three patients, and low C4 complement in five of the six. Symptoms were slow to resolve after penicillamine treatment was discontinued, and four of the patients needed corticosteroid therapy. A higher frequency than expected of HLA A 11 in three patients and B 15 in five patients was seen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6958210     DOI: 10.7326/0003-4819-97-5-659

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 2.  The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis.

Authors:  L E Hart; P Tugwell
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

3.  Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features.

Authors:  C A Brand; M J Rowley; B D Tait; K D Muirden; S F Whittingham
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Thyroid function and immune profile in rheumatoid arthritis. A controlled study.

Authors:  A P Andonopoulos; V Siambi; M Makri; M Christofidou; C Markou; A G Vagenakis
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

Review 5.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

6.  D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?

Authors:  A P Andonopoulos; E Terzis; E Tsibri; C A Papasteriades; T Papapetropoulos
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 7.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

8.  Antibodies to cellular antigens in Greek patients with autoimmune rheumatic diseases: anti-Ro(SSA) antibody a possible marker of penicillamine-D intolerance.

Authors:  H M Moutsopoulos; H Giotaki; P J Maddison; A C Mavridis; A A Drosos; F N Skopouli
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

Review 9.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun

10.  Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus.

Authors:  A A Borg; M J Davis; P T Dawes; M F Shadforth
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.